Pharmacological evaluation underlying the antinociceptive activity of 2 new hybrids NSAIDs tetrahydropyran derivatives.
The development of analgesic drugs is still a necessity due to the inefficiency of the current treatments for some pathological conditions and also due to the adverse effects produced by these drugs. The aim in this study was to deepen the pharmacological study of 2 new hybrids NSAIDs tetrahydropyran derivatives, regarding theirs antinociceptive effects on acute pain in mice. Male swiss mice were evaluated in the acetic acid-induced abdominal writhing, formalin, tail flick, open field, Glutamate and capsaicin induced paw licking tests, in vitro Cox inhibition assay, besides the acute toxicological evaluation. The compounds had effect on the acetic acid-induced abdominal writhing, formalin (both phases) and tail flick tests. In the study of the mechanism of action was observed reversion of the antinociceptive effect of the compounds from the previous administration of naloxone, L-NAME (L-nitro arginine methyl ester), ODQ (1H-[1,2,4]oxadiazolo[4,3-a]quinoxalin-1-one), glibenclamide, Nor-Binaltorphimine, by the intrathecal and intraperitoneal routes. The prior administration of MK-801 suggests that the modulation of NMDA receptor contribute to the antinociceptive effect of compounds. In summary, hybrid compounds presented central antinociceptive effect, demonstrating participation of the NO-cGMP-K+ ATP pathway, κ-opioid and NMDA receptors. In addition the compounds showed inhibition of cyclooxygenase enzymes and adverse effects were not observed with dose 300 times greater than the dose used experimentally.